Sugi Predict

Sugi Predict / Compounds / SCHEMBL622397

SCHEMBL622397

SCHEMBL622397

C[C@](N)(C(=O)O)c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NAPRT Q6XQN6 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ P4HTM Q9NXG6 1/20 0.42
▸ BLM P54132 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ SLC22A2 O15244 1/20 0.42
▸ SLC22A1 O15245 1/20 0.42
▸ PGR P06401 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ ADRB3 P13945 1/20 0.42
▸ OPRK1 P41145 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ SLC47A1 Q96FL8 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31073982 1.00 L3MBTL1 (0.48) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
SCHEMBL2086831 1.00 L3MBTL1 (0.48) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
SCHEMBL14184223 0.85 SMN1; SMN2 (0.48) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
SCHEMBL28996600 0.85 SMN1; SMN2 (0.48) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
SCHEMBL29282181 0.84 SMN1; SMN2 (0.47) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
SCHEMBL505194 0.81 L3MBTL1 (0.52) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
SCHEMBL5074249 0.81 L3MBTL1 (0.52) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
SCHEMBL1827357 0.79 L3MBTL1 (0.55) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
SCHEMBL1026708 0.78 L3MBTL1 (0.48) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM
Hydrochloric Acid SCHEMBL17102116 0.78 L3MBTL1 (0.53) L3MBTL1SMN1; SMN2NAPRTLMNAP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796766-B2 Potent and selective inhibitors of NAV1.3 and NAV1.7 AMGEN INC. (US) 2017-10-24 — — US claimed
US-9745359-B2 Protein and protein conjugate for diabetes treatment, and applications thereof ADDA BIOTECH INC. (CN) 2017-08-29 — — US claimed
US-20160304570-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 AMGEN INC. (US) 2016-10-20 — — US claimed
US-9340590-B2 Potent and selective inhibitors of NaV1.3 and NaV1.7 AMGEN INC. (US) 2016-05-17 — — US claimed
US-20150183847-A1 PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF ADDA BIOTECH INC. (CN) 2015-07-02 — — US claimed
EP-2851429-A1 PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF Adda Biotech Inc. (CN) 2015-03-25 — — EP claimed
US-20140073577-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 AMGEN INC. (US) 2014-03-13 — — US claimed
EP-2686340-A2 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 Amgen Inc. (US) 2014-01-22 — — EP claimed
WO-2012125973-A2 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 AMGEN INC. (US) 2012-09-20 — — WO claimed
EP-1704165-B1 GLP-1 COMPOUNDS NOVO NORDISK AS (DK) 2010-03-17 — — EP claimed
CN-114585637-B MASP-inhibitory compounds and uses thereof 拜耳公司 2025-04-15 — — CN disclosed
US-20240327461-A1 APELIN POLYPEPTIDES AMGEN INC. (US) 2024-10-03 — — US disclosed
CN-113967258-B FAP-activated therapeutic agents and related uses 塔夫茨大学信托人 2024-07-02 — — CN disclosed
US-11807693-B2 Apelin polypeptides AMGEN INC. (US) 2023-11-07 — — US disclosed
EP-4257152-A2 APELIN POLYPEPTIDES Amgen Inc. (US) 2023-10-11 — — EP disclosed
WO-2008088422-A2 TOXIN PEPTIDE THERAPEUTIC AGENTS AMGEN INC. (US) 2008-07-24 — — WO disclosed
EP-1940452-A2 CGRP PEPTIDE ANTAGONISTS AND CONJUGATES Amgen, Inc (US) 2008-07-09 — — EP disclosed
WO-2008011168-A2 GLYCOSYLATED PEPTIDE ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR AMGEN INC. (US) 2008-01-24 — — WO disclosed
US-20080020978-A1 CGRP peptide antagonists and conjugates AMGEN INC. 2008-01-24 — — US disclosed
WO-2007048026-A2 CGRP PEPTIDE ANTAGONISTS AND CONJUGATES AMGEN INC. (US) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073577-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 SCN7A, SCN3A, SCN9A L3MBTL1 1672/4885SMN1; SMN2 85/4885NAPRT 649/4885
US-20080020978-A1 CGRP peptide antagonists and conjugates GRPR, CALCRL, CALCA L3MBTL1 3968/4885SMN1; SMN2 1411/4885NAPRT 1635/4885
US-11807693-B2 Apelin polypeptides APLNR, FABP3, AP3B1 L3MBTL1 826/4885SMN1; SMN2 787/4885NAPRT 4039/4885
US-20240327461-A1 APELIN POLYPEPTIDES APLNR, FABP3, AP3B1 L3MBTL1 826/4885SMN1; SMN2 787/4885NAPRT 4039/4885
US-20160304570-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 SCN7A, SCN3A, SCN9A L3MBTL1 1672/4885SMN1; SMN2 85/4885NAPRT 649/4885
US-20150183847-A1 PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF GLP1R, GIPR, IAPP L3MBTL1 1594/4885SMN1; SMN2 2652/4885NAPRT 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.